- Copyright © 2011, The American Academy of Pediatrics
Children ages 9 to 23 months who are at high risk for meningococcal disease should be vaccinated with the quadrivalent meningococcal vaccine, according to a new recommendation by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC).
The guidance was adopted June 22 at the ACIP meeting in Atlanta.
High-risk children include those with complement component deficiencies, infants in a defined risk group for a community or institutional outbreak, and those traveling to areas where meningococcal disease is epidemic or highly endemic. This specific group of high-risk children would be administered vaccine in two doses three months apart.
In April the Food and Drug Administration (FDA) approved Menactra, the quadrivalent meningococcal vaccine from Sanofi Pasteur, as a two-dose primary series for children as young as 9 months. That vaccine already was approved for patients from ages 2 to 55 years. Menveo, from Novartis, has not been approved for children younger than 2.
Both Menactra and Menveo are used to protect against invasive meningococcal disease caused by Neisseria meningitides serotypes A, C, Y and W-135.
ACIP also voted to include the new recommendation in the Vaccines for Children Program.
More discussion about infant meningococcal vaccination is expected at ACIP’s next meeting in October.
ACIP recommendations are not official until approved by the CDC director and published in Morbidity and Mortality Weekly Report.
For complete coverage, look to future issues of AAP News.